Pancreatic polypeptide (PP) selectively activates NPY4 receptors, a signaling pathway that may become impaired as NPY levels decline during Alzheimer’s disease progression. Researchers from Henan University of Chinese Medicine described P1642-1, a novel PP analogue, in the 5×FAD mouse model of AD.